CoChat

Facts and controversies in the use of trastuzumab in the adjuvant setting

Dinh, Phuong, de Azambuja, Evandro, Cardoso, Fatima, Piccart-Gebhart, Martine J · 2008 · Nature Clinical Practice Oncology

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

The human epidermal growth factor receptor-2 (HER2) is overexpressed and/or amplified in up to 25% of breast cancer patients, and this feature is associated with an aggressive phenotype, high recurrence rate and reduced survival. Until recently, combination chemotherapy (with or without endocrine therapy) was the only effective adjuvant treatment for HER2-positive patients. Trastuzumab is a monoclonal antibody directed against the HER2 extracellular domain, and five recent adjuvant breast cancer trials have demonstrated an astonishing and highly reproducible benefit in halving the recurrence rate and reducing mortality in patients with this phenotype. Many questions related to trastuzumab use in the adjuvant setting still remain; these include the optimum timing and duration of treatment, trastuzumab use with taxanes and radiotherapy, its role in small node-negative tumors, the optimum chemotherapy regimens and cost-effectiveness. This Review outlines the five adjuvant trastuzumab studies and discusses the controversies and challenges that have emerged for both the clinician and healthcare authorities worldwide as a consequence of the results from these trials.

Overview

Integrity signals

Registry

Crossref · 10.1038/ncponc1219

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Research works printed but not linked: 2

  1. Slamon D et al. (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 100: S2
  2. Mackey JR et al. (2006) Trastuzumab prolongs progression-free survival in hormone-dependent and HER-2 positive metastatic breast cancer. Presented at the San Antonio Breast Cancer Symposium. 2006 December 14–17 [ http://www.abstracts2view.com/sabcs06/view.php?nu=SABCS06L_665 ]

Cited by

See all 19

Metadata

Authors
Dinh, P., de Azambuja, E., Cardoso, F., & Piccart-Gebhart, M. J.
Affiliations
Institut Jules Bordet (BE)
Venue
Nature Clinical Practice Oncology
Published
2008-09-09
Volume
5
Issue
11
Pages
645-654
ISSN
  • 1743-4254 (ISSN-L)
  • 1743-4262
OpenAlex
W1966520215
Cited by
19
References
52
Citations by year
2023: 1 · 2014: 1 · 2013: 1 · 2012: 1
FWCI
0.47
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Clinical Practice Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
trastuzumab, HER2-positive breast cancer, adjuvant therapy, HER2 overexpression, taxanes, radiotherapy, node-negative breast cancer, cost-effectiveness, recurrence rate, mortality
MeSH terms
Trastuzumab, Antibodies, Monoclonal, Antineoplastic Agents, Belgium, Breast Neoplasms, Clinical Trials as Topic, Cost-Benefit Analysis, Female, Humans, Neoplasm Recurrence, Local, Phenotype, Biomarkers, Tumor, Survival Analysis, Treatment Outcome, Chemotherapy, Adjuvant, Risk Assessment, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Facts and controversies in the use of trastuzumab in the adjuvant setting. https://app.cochat.ai/papers/10.1038/ncponc1219
The paper
Dinh, P., de Azambuja, E., Cardoso, F., & Piccart-Gebhart, M. J. (2008). Facts and controversies in the use of trastuzumab in the adjuvant setting. Nature Clinical Practice Oncology. https://doi.org/10.1038/ncponc1219

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.